Alnylam Pharmaceuticals, Inc.(ALNY)
Biotechnology
Rare Disease / Orphan Drug
| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | PYOTT DAVID E I Director | Sale | -3,830 | -70.77%1,582 | $299.18 | $1,145,853 | View SEC filing | |
| 2026-04-07 | McLaughlin Melissa Chief Human Resources Officer | Sale | -3,910 | -29.28%9,443 | $325.92 | $1,274,343 | View SEC filing | |
| 2026-03-06 | Garg Pushkal EVP Chief R&D | Sale | -4,713 | -20.14%18,693 | $323.53 | $1,524,796 | View SEC filing | |
| 2026-03-06 | Greenstreet Yvonne Chief Executive Officer | Sale | -2,933 | -2.97%95,695 | $323.08 | $947,581 | View SEC filing | |
| 2026-03-06 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | -2,468 | -3.84%61,805 | $323.08 | $797,351 | View SEC filing | |
| 2026-03-06 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | -2,309 | -6.31%34,297 | $323.08 | $745,984 | View SEC filing | |
| 2026-03-06 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | -1,291 | -5.91%20,569 | $323.54 | $417,685 | View SEC filing | |
| 2026-03-04 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | -2,206 | -3.32%64,273 | $327.65 | $722,801 | View SEC filing | |
| 2026-03-04 | Garg Pushkal EVP Chief R&D | Sale | -3,492 | -12.98%23,406 | $323.63 | $1,130,131 | View SEC filing | |
| 2026-03-04 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | -3,250 | -12.94%21,860 | $323.62 | $1,051,773 | View SEC filing | |
| 2026-03-04 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | -1,598 | -4.18%36,606 | $327.65 | $523,584 | View SEC filing | |
| 2026-03-04 | Greenstreet Yvonne Chief Executive Officer | Sale | -6,799 | -6.45%98,628 | $327.65 | $2,227,698 | View SEC filing | |
| 2026-03-02 | Garg Pushkal EVP Chief R&D | Sale | -4,627 | -17.29%22,129 | $331.34 | $1,533,100 | View SEC filing | |
| 2026-02-17 | Garg Pushkal EVP Chief R&D | Sale | -2,242 | -8.28%24,848 | $310.08 | $695,201 | View SEC filing | |
| 2026-02-17 | Greenstreet Yvonne Chief Executive Officer | Sale | -6,958 | -7.51%85,662 | $310.08 | $2,157,542 | View SEC filing | |
| 2026-02-17 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | -1,959 | -5.81%31,769 | $310.08 | $607,448 | View SEC filing | |
| 2026-02-17 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | -4,000 | -15.83%21,264 | $321.24 | $1,284,980 | View SEC filing | |
| 2026-02-17 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | -2,242 | -3.61%59,802 | $310.08 | $695,201 | View SEC filing | |
| 2026-01-14 | Garg Pushkal EVP Chief R&D | Sale | -1,510 | -6.29%22,511 | $362.87 | $547,929 | View SEC filing | |
| 2026-01-14 | Greenstreet Yvonne Chief Executive Officer | Sale | -9,577 | -10.88%78,411 | $362.86 | $3,475,157 | View SEC filing | |
| 2026-01-14 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | -2,780 | -4.61%57,465 | $362.87 | $1,008,766 | View SEC filing | |
| 2026-01-14 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | -1,510 | -4.83%29,728 | $362.87 | $547,927 | View SEC filing | |
| 2026-01-14 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | -3,800 | -15.16%21,264 | $367.37 | $1,395,992 | View SEC filing | |
| 2025-11-19 | Fitzgerald Kevin Joseph CSO & EVP, Head of Research | Sale | -12,128 | -36.32%21,264 | $452.18 | $5,483,990 | View SEC filing | |
| 2025-11-14 | Greenstreet Yvonne Chief Executive Officer | Sale | -25,650 | -19.31%65,409 | $452.75 | $11,613,003 | View SEC filing |
1-25 of 357